Related Experiment Video

Updated: Mar 18, 2026

Micropatterned Surfaces to Study Hyaluronic Acid Interactions with Cancer Cells
10:13

Micropatterned Surfaces to Study Hyaluronic Acid Interactions with Cancer Cells

Published on: December 22, 2010

15.6K

A site-selective hyaluronan-interferonα2a conjugate for the treatment of ovarian cancer

Isabella Monia Montagner1, Anna Merlo1, Debora Carpanese2

  • 1Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.

Journal of Controlled Release : Official Journal of the Controlled Release Society
|June 30, 2016
PubMed

Insights

Hyaluronic acid-conjugated interferon alpha 2a (HA-IFNα2a) offers a targeted ovarian cancer (OC) treatment. This bioconjugate enhances therapeutic effects and survival in preclinical models with reduced toxicity.

Area of Science:

  • Bioconjugation Chemistry
  • Oncology
  • Immunotherapy

Background:

  • Interferon alpha (IFNα) has limited efficacy and significant side effects in ovarian cancer (OC) treatment.
  • Targeted delivery strategies are needed to improve IFNα efficacy and reduce systemic toxicity in OC.

Purpose of the Study:

  • To develop and characterize a novel hyaluronic acid-IFNα2a (HA-IFNα2a) bioconjugate for targeted OC therapy.
  • To evaluate the biochemical, biological, and in vivo efficacy of the HA-IFNα2a bioconjugate in OC models.

Main Methods:

  • Conjugation of IFNα2a with aldehyde-modified hyaluronic acid (HA).
  • Biochemical and biological characterization of the HA-IFNα2a bioconjugate, including antiviral and anti-proliferative assays.
  • In vivo biodistribution studies using optical imaging.
  • Evaluation of therapeutic efficacy in ovarian cancer xenograft mouse models.

Main Results:

  • The HA-IFNα2a bioconjugate retained the antiviral and anti-proliferative activities of IFNα2a.
  • HA-IFNα2a showed prolonged persistence in the peritoneal cavity compared to free IFNα2a without causing organ toxicity.
  • The bioconjugate significantly improved survival rates in OC xenograft mouse models.

Conclusions:

  • HA-IFNα2a bioconjugate is a promising strategy for loco-regional ovarian cancer treatment.
  • Targeted delivery via HA conjugation enhances therapeutic efficacy and reduces systemic side effects of IFNα.
  • This approach warrants further investigation for clinical application in ovarian cancer.
Keywords:
HAylationHyaluronanInterferonOvarian cancerTumor targeting

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

10.0K
An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses10:35

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

Published on: November 28, 2010

19.0K

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
1
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K